Nuvation Bio (NUVB) announced that Japan’s Ministry of Health, Labour and Welfare has approved Ibtrozi for the treatment of adult patients with ROS1-positive unresectable, advanced and/or recurrent non-small cell lung cancer. As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commercialize Ibtrozi in Japan.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC Treatment
- Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for Glioma Treatment
- Nuvation Bio announces new data from Phase 2 studies of IBTROZI
- Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for IDH1 Mutant Glioma
- Nuvation Bio’s Milestone with FDA Approval of IBTROZI